{
    "clinical_study": {
        "@rank": "41965", 
        "arm_group": {
            "arm_group_label": "Imagine studies", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot sub-study of patients receiving myeloablative transplant using total body\n      irradiation (TBI) or total marrow irradiation (TMI) in their preparative regimen. The\n      objective of this stub-study is to estimate the heterogeneity in cellular proliferation\n      (FLT-PET uptake) as well the heterogeneity in marrow composition distribution (measured\n      using whole body water-fat MRI) using positron emission tomography imaging. This will be\n      used to design future trials as well as to determine the feasibility of PET and MRI imaging."
        }, 
        "brief_title": "Positron Emission Tomography (PET) in Heme Malignancy With Totay Body Irradiation (TBI) or Total Marrow Irradiation (TMI) in Hematopoietic Stem Cell Transplant", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Leukemia", 
        "condition_browse": {
            "mesh_term": "Leukemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of acute leukemia for which a myeloablative hematopoietic stem cell\n             transplant is planned through one of the following University of Minnesota protocols:\n\n               -  MT2006-24 \"Total Marrow Irradiation and Myeloablative Chemotherapy Followed by\n                  Double Umbilical Cord Blood Transplantation in Patients with Refractory Acute\n                  Leukemia\"\n\n               -  Any one of the current University of Minnesota myeloablative trials using total\n                  body irradiation\n\n          -  Aged 18 through 55 years\n\n          -  Women of childbearing potential must agree to use adequate contraception (diaphragm,\n             birth control pills, injections, intrauterine device [IUD], surgical sterilization,\n             subcutaneous implants, or abstinence, etc.) for the duration of the study (3 months\n             post HSCT)\n\n          -  Able and willing to provide written consent\n\n        Exclusion Criteria:\n\n          -  Otherwise eligible patients meeting one or more of the contraindicates for an MRI,\n             may enroll in the study without undergoing the MRI:\n\n               -  ferromagnetic implants\n\n               -  history of shrapnel or shot gun injury\n\n               -  too large to fit in the magnet (approximate body mass index \u2265 40)\n\n               -  cardiac pacemakers or other implanted devices that are not MR-compatible\n\n               -  claustrophobia\n\n               -  large tattoos"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042924", 
            "org_study_id": "2013NTLS100", 
            "secondary_id": "MT2013-28R"
        }, 
        "intervention": [
            {
                "arm_group_label": "Imagine studies", 
                "description": "Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).", 
                "intervention_name": "FLT PET/CT", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Imagine studies", 
                "description": "MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).", 
                "intervention_name": "MRI", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "acute myelogenous leukemia", 
            "acute lymphoblastic leukemia", 
            "AML", 
            "ALL", 
            "myeloablative hematopoietic stem cell transplant"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "tkrepsk1@fairview.org", 
                "last_name": "Timothy Krepski", 
                "phone": "612-273-2800"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota Masonic Cancer Center"
            }, 
            "investigator": {
                "last_name": "Susanta K Hui, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Positron Emission Tomography (PET) Imaging in Patients With High Risk Hematological Malignancies Receiving Total Body Irradiation (TBI) or Total Marrow Irradiation (TMI) as Part of a Hematopoietic Stem Cell Transplant", 
        "overall_contact": {
            "email": "tkrepsk1@fairview.org", 
            "last_name": "Timothy Krepski", 
            "phone": "612-273-2800"
        }, 
        "overall_contact_backup": {
            "email": "shanb007@umn.edu", 
            "last_name": "Neeta Shanbhag, MPH", 
            "phone": "612-626-4373"
        }, 
        "overall_official": {
            "affiliation": "University of Minnesota - Clinical and Translational Science Institute", 
            "last_name": "Susanta K Hui, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The difference in the percentage of proliferating bone marrow between baseline and day 100 post transplant at the following sites: skull, proximal humeri, ribs, clavicles, cervical spine, thoracic spine, lumbar spine, sacrum, pelvis and proximal femur.", 
                "measure": "Percentage of proliferating bone marrow", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }, 
            {
                "description": "The difference in the water-fat MRI between baseline and day 100 post transplant in L4 and femoral neck", 
                "measure": "Difference in water fat", 
                "safety_issue": "No", 
                "time_frame": "100 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042924"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}